Egg Yolk Antibody against Infectious Bursal Disease
- For emergency treatment and emergency prevention during the early and middle stages of infectious bursal disease in chickens.
- Manufacturing: Produced in GMP-certified facility
- Supply Mode: Bulk Supply / Distributor / OEM Available
- Origin: China
Generic Name
Egg Yolk Antibody against Infectious Bursal Disease
Composition and Content
This product contains egg-yolk antibodies against infectious bursal disease virus. The antibody titer by agar gel precipitation test shall be ≥1:48.
Appearance
A transparent, light-brown or pale-yellow liquid. A small amount of white sediment may form at the bottom after prolonged standing. The pH shall be 6.8-7.2.
Indications
For emergency treatment and emergency prevention during the early and middle stages of infectious bursal disease in chickens.
Dosage and Administration
Administer by subcutaneous, intramuscular, or intraperitoneal injectio
Treatment dose: 2 mL per chicken up to 35 days of age; 3 mL per chicken over 35 days of age.
Emergency prevention dose: 1.0 mL per bird up to 25 days of age; 1.5 mL per bird at 25-35 days; 2.0 mL per bird at 35-45 days; and 2.5-4.0 mL per bird over 45 days. If necessary, repeat the injection 2-3 times.
Adverse Reactions
Generally, no adverse reactions occur.
Precautions
- 1. Each injection provides passive immune protection for 5-7 days.
- 2. This product is ineffective when administered orally.
- 3. This product may be administered 2-3 consecutive times.
- 4. This product may contain antibodies against multiple pathogens in addition to infectious bursal disease virus. Do not administer live infectious bursal disease, Newcastle disease, or infectious bronchitis vaccines within 5 days after use.
- 5. This product may be mixed with kanamycin or gentamicin for injection.
- 6. A small amount of flocculent sediment at the bottom after prolonged standing does not affect efficacy.
Specification
250 mL/bottle, 40 bottles/carton; 500 mL/bottle, 20 bottles/carton.
Storage and Shelf Life
Store at 2-8°C. Shelf life: 24 months.
1. Dual-Strain Broad Protection
- 1. One injection provides four protections – an innovative breakthrough in China that improves disease prevention efficiency, enhances effectiveness, and reduces farm workload.
- 2. Serotype-matched, highly concentrated viral subunit antigens formulated in scientifically optimized proportions.
- 3. Adjuvant formulation ensures zero stress and delivers high-efficiency protection using compound vegetable oil technology.
- 4. The vaccine contains composite antigens from classical very virulent Infectious Bursal Disease virus (cvvIBDV) and novel variant IBDV (nvIBDV), offering improved cross-protection against both strains as an upgraded version of the company’s original inactivated IBD vaccine series.
- 5. The adoption of a customized H9 Avian Influenza strain model enables meeting the needs of different countries for prevalent strains.